Introduction {#Sec1}
============

Human papillomavirus (HPV) is generally accepted as the causative agent of cervical cancer (CC) \[[@CR1]\], which was first unmasked by the landmark studies of Meisels and Fortin \[[@CR2]\] and Purola and Savia \[[@CR3]\]. Currently, there are 198 reference HPV types listed on Papillomavirus Episteme (PaVE) database, and at least 12 were classified as high-risk by World Health Organization (WHO) International Agency for Research on Cancer (IARC) Monographs Working Group \[[@CR4]--[@CR6]\]. HPV testing has been adopted by several European countries for primary CC screening, to augment cytology-based screening programs \[[@CR7], [@CR8]\]. A number of HPV assays are available commercially, which are mainly based on direct HPV genome detection, HPV DNA amplification and E6/ E7 mRNA detection \[[@CR9]\]. Recent advent of next-generation sequencing (NGS) technologies has facilitated high throughput tools for infectious disease diagnostics and epidemiological research. Several research groups have explored utility of Illumina MiSeq and Ion Torrent platforms for HPV genotyping, with comparable sensitivity to well-established line blot assays and broader detection spectrum \[[@CR10]--[@CR12]\]. While the reagent cost is comparable to existing commercial assays for large sample batches, these NGS platforms may not be the best choice for medium sample throughput and laboratories with less resources and space. In this regard, portable Nanopore sequencers may allow more flexibility with shorter sequencing time and lower reagent cost. In light of this, we developed a Nanopore HPV genotyping protocol using 2 published primer sets, and compared its performance with 2 commercial HPV assays: cobas HPV Test and Roche Linear Array HPV Genotyping Test (LA).

Methods {#Sec2}
=======

Specimens {#Sec3}
---------

Two hundred and one cervicovaginal swabs were collected from March to July, 2019 in Hong Kong Sanatorium & Hospital. The swabs were preserved in SurePath preservative fluid (Becton, Dickson and Company, Sparks, MD, USA) and routinely tested for Papanicolaou smear (Pap smear, following The Bethesda System for reporting), cobas HPV Test and LA (Roche Diagnostics, Mannheim, Germany). Routine test results are shown in Table [1](#Tab1){ref-type="table"}. Table 1Results of Pap smear, cobas HPV Test, Roche Linear Array HPV Genotyping Test, and Nanopore sequencingPatientPap smearRoche Linear ArrayCobas HPVNanopore (PGMY)Nanopore (MGP)Total HPV readsHRNon-HRHRNon-HRHRNon-HR1AGUSNegNegNegNegNegNegNegND2ASCH52, 5962Other HR59Neg599049563ASCUS5255Neg5255NegNeg42624ASCUSNegNegNegNegNegNegNegND5ASCUS31, 3354Other HR31, 33, 52NegNeg9089736ASCUSNegNegNegNegNegNegNegND7ASCUS31NegOther HRNegNeg31Neg14308ASCUSNegNegNegNegNegNegNegND9ASCUSNeg81NegNeg81Neg8148,47710ASCUS18Neg1818Neg18Neg16,20611ASCUSNegNegNegNegNegNegNegND12ASCUSNegNegNegNegNegNegNegND13ASCUS5253, 54Other HR5244, 53, 745274, 9015,41914ASCUSNegNegNegNegNegNegNegND15ASCUSNegNegNegNegNegNegNegND16ASCUS5281Neg5281Neg81887317ASCUS5254Other HR5254525436,25818ASCUS52, 5911Other HR52, 591152, 591144,70219ASCUSNegNegNegPCR inhibition20ASCUSNegNegNegNegNegNegNeg721ASCUSNegNegNegNegNegNegNegND22ASCUSNegNegNegNegNegNegNegND23ASCUS3961, 72Other HR3961, 723987162424ASCUS66NegOther HR66Neg66Neg10,38325ASCUS6861Other HRNeg61Neg6110,64426ASCUSNegNegNegNegNegNeg9054127ASCUS52NegNeg52NegNeg87361428ASCUSNeg62NegNeg62Neg624529ASCUSNegNegNegNegNegNegNegND30ASCUS35NegOther HR35Neg35Neg164131ASCUSNegNegNegNegNegNegNegND32ASCUS52NegOther HR52Neg52Neg39933ASCUSNegNegNegNegNegNegNegND34ASCUS5184Other HR51NegNegNeg185335ASCUSNegNegNegNeg74Neg7411,49936ASCUSNegNegNegNegNegNegNeg9337ASCUS51NegOther HR51Neg51Neg289738ASCUSNeg40, 55, 83NegNeg40, 55, 83Neg40, 55, 8347,73639ASCUSNegNegNegNegNegNegNegND40ASCUS5853, 55, 62Other HR52, 5853, 55, 62, 745253, 62, 7442,10641ASCUS5242, 73Other HR5242, 735242, 7315,77842ASCUSNegNegNegNegNegNegNeg11643HSIL16Neg1616Neg16Neg15,91844HSIL16Neg1616Neg16Neg34,65445HSIL59NegOther HR59Neg59Neg15,38146HSIL31, 58NegOther HR31, 58Neg31, 58Neg336747LSIL52, 6884Other HR52, 688452, 6884, 9024,36648LSIL6684Other HR6644, 84664457,20649LSIL52NegNeg52Neg52Neg14,51650LSILNeg40, 53NegNeg40, 53Neg40, 53926551LSIL5211, 81Other HR5211, 815211, 43, 8129,74852LSIL66NegOther HR66Neg66Neg40,32853LSIL51NegOther HR51Neg5143, 90445454LSIL16, 51, 5654, 62, 8116, other HR16, 51, 5654, 62, 8116, 5140, 62, 8120,45555LSIL5653Other HR5653565328,37756LSILNegNegNegNegNegNegNegND57LSIL6654, 55, 81Other HR6654, 55, 816655, 81, 9025,60658LSIL52NegNeg5242529015,10359LSIL59NegOther HR59NegNegNeg11,23560LSIL5989Neg5989Neg8967,22061LSIL5682Other HR56825643, 8242,16062LSIL52NegOther HR52Neg52Neg39,32363LSIL33, 51NegOther HR33, 5144514419,70464LSIL+ ASCH51NegOther HR51Neg51Neg462165NIL16Neg1616Neg16Neg195866NILNegNegNegNegNegNegNegND67NILNegNegNegNegNegNegNegND68NILNegNegNeg59Neg59Neg245569NILNegNegNegNeg87Neg87877570NILNegNegNegNegNegNegNegND71NILNegNegNegNegNegNegNegND72NILNegNegNegNegNegNegNegND73NILNegNegNegNegNegNegNegND74NIL58NegOther HR58Neg52, 5862861975NIL58NegOther HR58Neg58Neg13,14976NILNegNegNegNegNegNegNegND77NILNegNegNegNegNegNegNegND78NILNegNegNegNegNegNeg90228979NIL5670Other HRNeg44, 705644, 70785580NILNegNegNegPCR inhibition81NILNegNegNegNegNegNegNeg7482NILNeg42NegNegNegNeg42140683NILNegNegNegNeg74Neg74744184NILNegNegNegNegNegNegNegND85NILNeg82NegNeg82Neg82116286NILNeg62NegNeg62Neg6265,36887NILNegNegNegNegNegNegNegND88NILNegNegNegNegNegNegNegND89NILNegNegNegNegNegNegNegND90NILNegNegNegNegNegNegNeg14291NIL39, 52NegOther HR52Neg529015,70392NIL68NegOther HR684268Neg19,77793NILNegNegNegNegNegNegNegND94NILNegNegNegNegNegNegNegND95NILNegNegNegNegNegNegNegND96NIL52NegNeg52Neg52Neg524297NILNegNegNegNegNegNegNegND98NILNegNegNegNegNegNegNegND99NILNegNegNegNegNegNegNeg41100NIL52NegOther HR52Neg52Neg24,478101NILNeg61NegPCR inhibition102NILNegNegNegNegNegNegNeg72103NIL39NegNegNegNegNegNegND104NILNeg62, 84NegNeg62Neg623589105NILNeg71NegNegNegNegNegND106NILNegNegNegNegNegNegNegND107NIL5262Other HR5244, 53, 62524418,086108NILNegNegNegNegNegNegNegND109NILNegNegNegNegNegNegNegND110NILNegNegNegNegNegNegNegND111NILNeg84NegNegNegNegNegND112NIL16, 52Neg1616, 52Neg16Neg72,357113NILNegNegNegNegNegNegNegND114NILNeg55, 89NegNeg26, 55, 895926, 55, 62, 898926115NILNegNegNegNegNegNeg741586116NILNeg81NegNegNegNegNegND117NILNegNegNegNegNegNegNegND118NILNeg6, 62NegNeg6, 62Neg6, 629414119NILNegNegNegNegNegNegNegND120NILNeg54NegNegNegNegNegND121NILNegNegNegPCR inhibition122NILNegNegNegNegNegNegNeg8123NIL68NegOther HRNegNegNegNegND124NILNeg81NegNeg81Neg818735125NILNeg84NegNegNegNeg871025126NILNegNegNegNegNegNeg901719127NILNegNegNegNegNegNegNegND128NILNegNegNegNegNegNegNegND129NILNegNegNegNegNegNegNeg10130NILNegNegNegNegNegNegNegND131NILNeg84NegNegNegNegNegND132NILNegNegNegNegNegNegNegND133NIL5962, 71Other HRNegNegNegNeg30134NILNegNegNegNegNegNegNegND135NILNegNegNegNegNegNegNeg522136NILNegNegNegNegNegNegNegND137NIL5184Other HRPCR inhibition138NIL39NegOther HR39Neg39Neg19,305139NILNegNegNegNegNegNegNeg195140NILNegNegNegNegNegNegNegND141NILNegNegNegNegNegNegNeg23142NILNegNegNegNegNegNegNegND143NILNeg42, 81NegNeg40, 74, 81Neg40, 74, 81, 8719,118144NILNegNegNegNegNegNegNegND145NILNegNegNegNegNegNegNegND146NILNegNegNegNegNegNegNegND147NILNegNegNegNegNegNegNeg40148NIL59NegNeg59NegNegNeg12,681149NILNegNegNegNegNegNegNeg14150NILNegNegNegPCR inhibition151NILNegNegNegNegNegNegNeg79152NILNeg62NegNeg62Neg6214,353153NILNegNegNegNegNegNegNegND154NILNegNegNegNegNegNegNegND155NILNegNegNegNegNegNegNegND156NIL5254Neg5254525418,397157NIL39, 5253, 61Other HR3953, 613953, 6120,332158NILNegNegNegNegNegNegNegND159NILNegNegNegNegNegNegNeg60160NILNegNegNegPCR inhibition161NILNeg62NegNeg62Neg6213,545162NILNegNegNegNeg74Neg744514163NILNeg62NegNeg62Neg6211,894164NILNegNegNegNegNegNegNegND165NIL59NegNegPCR inhibition166NILNegNegNegNegNegNegNegND167NIL39NegOther HR39Neg39Neg52,831168NILNegNegNegNegNegNegNegND169NILNegNegNegNegNegNegNegND170NIL66NegOther HR66Neg66Neg54,943171NILNegNegNegNegNegNegNegND172NILNegNegNegNegNegNegNegND173NILNegNegNegNegNegNegNegND174NIL66NegOther HR66Neg66Neg57,791175NILNeg54NegNeg54Neg5423,583176NILNegNegNegPCR inhibition177NIL166216Neg53, 62166228,181178NILNegNegNegNegNegNegNeg206179NILNegNegNegNegNegNegNegND180NILNegNegNegNegNegNegNegND181NIL51, 66NegOther HR51, 66, 68Neg51, 66, 68Neg6952182NIL16, 51, 5861Other HR5861Neg615737183NILNegNegNegNegNegNegNegND184NIL58NegOther HR58Neg58Neg43,034185NIL5870, 89Other HR5870, 89588933,842186NDNegNegNegNegNegNegNeg414187NDNegNegNegNegNegNegNegND188ND16Neg1616Neg16Neg96,549189NDNegNegNegNegNegNegNegND190NDNegNegNegNegNegNegNegND191ND56NegOther HR56Neg56Neg18,782192ND51NegOther HR51Neg51Neg6020193NDNeg62NegNeg62Neg6220,373194NDNegNegNegNegNegNegNegND195ND52, 59NegOther HR52, 59Neg59Neg11,926196ND59NegOther HR59Neg59Neg24,045197ND52, 5954, 70Other HR52, 597052, 5970, 9046,523198ND56, 6653, 61, 84Other HR6632, 53, 61, 845632, 53, 61, 8462,600199NDNeg62NegNegNegNegNegND200NDNeg53, 54, 81, 83NegNeg53, 54, 83Neg53, 81, 8332,868201NDNegNegNegPCR inhibition*AGUS* Atypical glandular cells of undetermined significance, *ASCH* Atypical squamous cells -- cannot exclude HSIL, *ASCUS* Atypical squamous cells of undetermined significance, *HR* High-risk, *HSIL* High-grade squamous intraepithelial lesion, *LSIL* Low-grade squamous intraepithelial lesion, *ND* Pap smear/ MinION sequencing not done, *Neg* Negative, *NIL* normal cytology

DNA extraction {#Sec4}
--------------

DNA extraction and cobas HPV Test were performed using cobas 4800 system (Roche Diagnostics, Rotkreuz, Switzerland). Briefly, 500 μL of cervicovaginal specimen was added to 500 μL of sample preparation buffer and heated at 120 °C for 20 min. The mixture was brought to ambient temperature for 10 min and processed on cobas × 480 using 'high-risk HPV DNA PCR' protocol. Real-time polymerase chain reaction (PCR) was performed on cobas z 480. Fifty microliter of DNA extract was used for LA according to manufacturer's recommendations. Residual DNA was used for Nanopore protocol after routine testing.

HPV PCR {#Sec5}
-------

For each specimen, L1 region of HPV genome was amplified in 2 separate PCRs using PGMY and MGP primer sets \[[@CR13], [@CR14]\]. Primer sequences and cycling conditions are shown in Tables [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"}. Human β-globin gene was used as inhibition control and contamination was monitored by negative extraction control. Five microliter of each PCR amplicon was electrophoresized in 2% agarose gel (Invitrogen, Carlsbad, CA, USA) and analyzed. PCR-positive specimens were sequenced using Nanopore MinION. Table 2Primer sequencesPrimer5′ to 3′ sequenceReferences**PGMY PCR** PGMY11-AGCA CAG GGA CAT AAC AAT GG\[[@CR13]\] PGMY11-BGCG CAG GGC CAC AAT AAT GG PGMY11-CGCA CAG GGA CAT AAT AAT GG PGMY11-DGCC CAG GGC CAC AAC AAT GG PGMY11-EGCT CAG GGT TTA AAC AAT GG PGMY09-FCGT CCC AAA GGA AAC TGA TC PGMY09-GCGA CCT AAA GGA AAC TGA TC PGMY09-HCGT CCA AAA GGA AAC TGA TC PGMY09-IG CCA AGG GGA AAC TGA TC PGMY09-JCGT CCC AAA GGA TAC TGA TC PGMY09-KCGT CCA AGG GGA TAC TGA TC PGMY09-LCGA CCT AAA GGG AAT TGA TC PGMY09-MCGA CCT AGT GGA AAT TGA TC PGMY09-NCGA CCA AGG GGA TAT TGA TC PGMY09-PG CCC AAC GGA AAC TGA TC PGMY09-QCGA CCC AAG GGA AAC TGG TC PGMY09-RCGT CCT AAA GGA AAC TGG TC HMB01GCG ACC CAA TGC AAA TTG GT Human β-globin forwardGAAGAGCCAAGGACAGGTAC\[[@CR15]\] Human β-globin reverseGGAAAATAGACCAATAGGCAG**MGP PCR** MGPAACGTTGGATGTTTGTTACTGTGGTGGATACTAC\[[@CR16]\] MGPBACGTTGGATGTTTGTTACCGTTGTTGATACTAC MGPCACGTTGGATGTTTGTTACTAAGGTAGATACCACTC MGPDACGTTGGATGTTTGTTACTGTTGTGGATACAAC MGP31ACGTTGGATGTTTGTTACTATGGTAGATACCACAC MGPGACGTTGGATGGAAAAATAAACTGTAAATCATATTCCT MGPHACGTTGGATGGAAAAATAAATTGTAAATCATACTC MGPIACGTTGGATGGAAATATAAATTGTAAATCAAATTC MGPJACGTTGGATGGAAAAATAAACTGTAAATCATATTC MGP18ACGTTGGATGGAAAAATAAACTGCAAATCATATTCTable 3Master mix constituents and PCR conditionsPGMY PCR***Master mix constituents (for single reaction)*ReagentVolume/μL**10X PCR buffer II (Applied Biosystems)525 mM MgCl~2~ (Applied Biosystems)3PGMY primer mix (10 μM)1Human β-globin primer mix (5 μM)110 mM dNTPs (Roche)15 M betaine (Sigma)10AmpliTaq Gold DNA Polymerase (Applied Biosystems)0.25Molecular grade water (Sigma)23.75DNA5***PCR conditions*Temperature/**^**o**^**CTimeNo. of cycles**959 min1951 min40 (50% ramp)551 min721 min725 min115Hold/MGP PCR***Master mix constituents (for single reaction)*ReagentVolume/μL**10X PCR buffer II (Applied Biosystems)2.525 mM MgCl~2~ (Applied Biosystems)1.5MGP primer mix (10 μM)0.510 mM dNTPs (Roche)0.5AmpliTaq Gold DNA Polymerase (Applied Biosystems)0.1Molecular grade water (Sigma)14.9DNA5***PCR conditions*Temperature/**^**o**^**CTimeNo. of cycles**9510 min19530 s54230 s7230 s9530 s456430 s7230 s725 min115Hold/

Nanopore sequencing library preparation {#Sec6}
---------------------------------------

PGMY and MGP PCR amplicons of each positive specimen were pooled and purified using AMPure XP beads (Beckman-Coulter, Brea, CA, USA). Nanopore sequencing libraries were prepared from purified amplicons using Ligation Sequencing Kit 1D (SQK-LSK109) and PCR-free Native Barcoding Expansion Kit (EXP-NBD104/114) (Oxford Nanopore Technologies, Oxford, England). The barcoded libraries were loaded and sequenced on MinION flow cells (FLO-MIN106D R9.4.1, Oxford Nanopore Technologies, Oxford, England) after quality control runs.

Data analysis {#Sec7}
-------------

Data from first 2 h of sequencing runs was analyzed. FASTQ files generated by live basecalling (MinKNOW version 2.0) were demultiplexed using 'FASTQ Barcoding' workflow on EPI2ME (Oxford Nanopore Technologies, Oxford, England) with default minimum qscore of 7, 'auto' and 'split by barcode' options. FASTQ files of each specimen were concatenated into a single file and analyzed using a 2-step custom workflow on Galaxy bioinformatics platform. Briefly, FASTQ files were converted into FASTA format, followed by aligning sequences against HPV reference genomes from PaVE database using NCBI BLAST+ blastn (Galaxy version 1.1.1). PGMY and MGP reads were sorted based on sequence length and analyzed individually. Threshold of each run was derived from average number of background reads plus 10 standard deviations, which were calculated using interquartile rule, excluding first and last quartiles. A positive HPV call was based on either (1) the number of reads for a particular HPV type was above threshold, or (2) the specimen had the highest number of reads for a particular HPV type. All positive calls were further assessed by aligning FASTQ sequences against HPV reference genomes using minimap2 (Galaxy version 2.17 + galaxy0), and consensus sequences were built from BAM files using Unipro UGENE (version 1.29.0) for determining their percentage of identity to reference genomes.

Results {#Sec8}
=======

As HPV 66 is categorized as 'other high-risk' by cobas HPV Test, all calculations were based on this grouping, albeit HPV 66 was found as a single infection in cancers with extreme rarity and re-classified as possible carcinogen (Group 2B) by IARC Monographs Working Group \[[@CR6]\].

The results are summarized in Table [1](#Tab1){ref-type="table"}. PCR was successful for 191 specimens (191/201, 95.02%), with 10 specimens (10/201, 4.98%) lacking β-globin band and therefore regarded as inappropriate for further analysis. Seventy-six specimens (76/201, 37.81%) were negative for both PGMY and MGP PCRs, and 115 (115/201, 57.21%) were positive for either of the two. PCR-positive specimens were sequenced on 10 MinION flow cells with 145--890 active pores, generating 31,748--525,880 HPV reads in first 2 h (Table [4](#Tab4){ref-type="table"}). For the 115 specimens sequenced, 19 were negative (7--522 reads, 113 in average) and 96 were positive (45--96,549 reads, 20,158 in average) for HPV. Taken together, there were 95 HPV-negative (95/201, 47.26%) and 96 HPV-positive (96/201, 47.76%) specimens by Nanopore workflow. Table 4Details of Nanopore sequencing runsRunNo. of active poresElapsed sequencing timeNo. of HPV reads16112 h 11 min60,97624581 h 59 min246,52136902 h 1 min279,52044672 h 5 min111,88554622 h 5 min31,74862472 h 3 min113,52173302 h 5 min111,70287532 h 1 min478,71191451 h 59 min207,094108901 h 59 min525,880

Table [5](#Tab5){ref-type="table"} shows concordance of Nanopore workflow with cobas HPV Test and LA, which was based on the 37 HPV types detectable by LA. For cobas HPV Test, our workflow achieved 93.19, 93.19 and 81.94% for perfect, total and positive agreement, respectively, with Cohen's kappa of 0.85. For LA, Nanopore achieved a perfect agreement of 83.77% for both high-risk and non-high risk HPVs. For high-risk types, total and positive agreement were 96.86 and 91.78%, respectively, with Cohen's kappa of 0.93. For non-high risk types, total and positive agreement were 93.19 and 77.59%, respectively, with Cohen's kappa of 0.83. Table 5Agreement between cobas HPV Test, Roche Linear Array HPV Genotyping Test (LA) and NanoporeNanoporePerfect agreementTotal agreementPositive agreementCohen's κ+--**cobas HPV Test+**59293.19%93.19%81.94%0.85**--**11119**LAHR+**67483.77%96.86%91.78%0.93**--**2118**Non-HR+**451093.19%77.59%0.83**--**3133

Table [6](#Tab6){ref-type="table"} shows per-type concordance of Nanopore and LA. A total of 13 high-risk and 19 non-high risk HPV types were evaluated. Positive agreement for HPV 16 (*n* = 8) and 18 (*n* = 1) were 87.5 and 100%, respectively. Positive agreement was 75--100% for high-risk HPV 31, 33, 35, 39, 51, 52, 56, 58, 59 and 66, and 20% for HPV 68 (*n* = 5). For non-high risk HPVs, positive agreement was 37.5--100% for HPV 6, 11, 40, 42, 53, 54, 55, 61, 62, 70, 72, 73, 81, 82, 83, 84 and 89. There were 2 non-high risk types with 0% positive agreement (HPV 26 and 71). HPV 26 (*n* = 1) was only detected by Nanopore workflow, whereas HPV 71 (*n* = 2) was only detected by LA. Table 6Per HPV type positive agreement between Roche Linear Array Genotyping Test (LA) and NanoporeHPV GenotypesNumber of specimensPositive agreementNanopore−/LA−/LA-Nanopore +/LA-Nanopore−/LA+Nanopore+/LA+Total**High-risk16**18301719187.5%**18**190001191100%**31**188003191100%**33**189002191100%**35**190001191100%**39**18501519183.33%**51**18201819188.89%**52**165322119180.77%**56**185006191100%**58**184007191100%**59**17921919175%**66**18210819188.89%**68**18622119120%**Non-high risk6**190001191100%**11**189002191100%**26**1901001910%**40**18720219150%**42**18621219140%**53**18130719170%**54**18104619160%**55**186005191100%**61**186005191100%**62**174221319176.47%**70**188003191100%**71**1890201910%**72**190001191100%**73**190001191100%**81**18201819188.89%**82**189002191100%**83**189002191100%**84**18305319137.5%**89**188003191100%

Table [7](#Tab7){ref-type="table"} reveals the percentage of identity of Nanopore consensus sequences to HPV reference genomes. In general, Nanopore consensus sequences showed an average identity of 98% to the best matches, with an average difference of 15% from second BLAST hits. Table 7Percentage of identity of Nanopore consensus sequences to HPV reference genomesPatientNanopore resultsBest BLAST hitSecond BLAST hitDifferenceHPV type% identityHPV type% identity**259**5999%1877%22%^**a**^**90**9097%10684%15%**352**5299%5880%19%**55**55100%4493%7%**531**3198%3580%18%**33**3399%5886%13%^**a**^**52**5299%5880%19%^**a**^**90**9097%10685%12%**731**3195%3579%16%**981**8199%6285%14%**1018**1899%4585%14%**13**^**a**^**44**4499%5592%7%**52**5299%5880%19%**53**5399%3085%14%^**a**^**74**7499%5583%16%^**a**^**90**9097%10685%12%**1652**5299%5881%18%**81**8199%6285%14%**1752**5299%5880%19%**54**5499%4574%25%**1811**1199%687%12%**52**5299%5880%19%**59**5999%1877%22%**2339**3999%7081%18%**61**6199%mEV06c12b83%16%**72**7292%mEV06c12b89%3%^**a**^**87**8798%8685%13%**2466**6698%5684%14%**2561**6199%mEV06c12b83%16%**26**^**a**^**90**9097%10685%12%**2752**5299%5880%19%^**a**^**87**8798%8684%14%**2862**6299%8184%15%**3035**3598%3180%18%**3252**5299%5881%18%**3451**5199%8285%14%**35**^**a**^**74**7499%5584%15%**3751**5199%8285%14%**3840**4099%788%11%**55**5599%4493%6%**83**8399%10284%15%**40**^**a**^**52**5299%5880%19%**53**5398%3085%13%**55**55100%4493%7%**58**5899%3386%13%**62**6299%8185%14%^**a**^**74**7498%5584%14%**4142**4298%3283%15%**52**52100%5881%19%**73**7399%3485%14%**4316**16100%3578%22%**4416**1699%3578%21%**4559**5999%1876%23%**4631**3198%3580%18%**58**5899%3386%13%**4752**5298%5880%18%**68**6893%3981%12%**84**8498%8784%14%^**a**^**90**9097%10685%12%**48**^**a**^**44**4499%5593%6%**66**6698%5684%14%**84**8499%8784%15%**4952**5299%5880%19%**5040**4098%787%11%**53**5398%3085%13%**5111**11100%687%13%^**a**^**43**4395%4577%18%**52**5299%5880%19%**81**8199%6284%15%**5266**6698%5683%15%**53**^**a**^**43**4395%4578%17%**51**5199%8284%15%^**a**^**90**9097%10685%12%**5416**16100%3578%22%^**a**^**40**4093%785%8%**51**5199%8284%15%**54**5499%4573%26%**56**5690%6676%14%**62**6299%8184%15%**81**8199%6285%14%**5553**5399%5679%20%**56**5699%6684%15%**5754**5487%3174%13%**55**55100%4493%7%**66**6698%5684%14%**81**8199%6284%15%^**a**^**90**9097%10685%12%**58**^**a**^**42**4299%3284%15%**52**5298%5880%18%^**a**^**90**9097%10685%12%**5959**5999%1877%22%**6059**5999%1876%23%**89**8999%8178%21%**61**^**a**^**43**4396%4579%17%**56**5697%6683%14%**82**8299%5184%15%**6252**5299%5880%19%**6333**3399%5886%13%^**a**^**44**4499%5593%6%**51**5199%8283%16%**6451**5199%8284%15%**6516**16100%3578%22%**68**^**a**^**59**5999%1877%22%**69**^**a**^**87**8799%8686%13%**74**^**a**^**52**5299%5881%18%**58**5899%3386%13%^**a**^**62**6299%8185%14%**7558**5899%3385%14%**78**^**a**^**90**9097%10685%12%**79**^**a**^**44**4499%5592%7%**56**5696%6684%12%**70**7099%3981%18%**81**^**a**^**74**7493%5581%12%**8242**4295%3283%12%**83**^**a**^**74**7497%5583%14%**8582**8299%5184%15%**8662**6299%8185%14%**9152**5299%5880%19%^**a**^**90**9097%10684%13%**92**^**a**^**42**4293%3278%15%**68**6892%3980%12%**9652**5299%5880%19%**10052**5299%5880%19%**10462**6298%8185%13%**107**^**a**^**44**4499%5593%6%**52**5299%5881%18%^**a**^**53**53100%3086%14%**62**6299%8185%14%**11216**1698%5878%20%**52**5299%5881%18%**114**^**a**^**26**26100%6983%17%**55**55100%4493%7%^**a**^**59**5999%1877%22%^**a**^**62**6299%8185%14%**89**8999%8177%22%**115**^**a**^**74**7495%5583%12%**1186**699%1187%12%**62**6299%8184%15%**12481**8199%6285%14%**125**^**a**^**87**8798%8685%13%**126**^**a**^**90**9097%10685%12%**13839**3999%6881%18%**143**^**a**^**40**4099%788%11%^**a**^**74**7498%5584%14%**81**8199%6284%15%^**a**^**87**8797%8684%13%**14859**5999%1877%22%**15262**6298%8185%13%**15652**5299%5881%18%**54**5495%674%21%**15739**3994%7081%13%**53**5396%3084%12%**61**6199%mEV06c12b83%16%**16162**6298%8183%15%**162**^**a**^**74**7494%5585%9%**16362**6299%8185%14%**16739**3999%7081%18%**17066**6698%5683%15%**17466**6698%5683%15%**17554**5499%4573%26%**17716**1699%3580%19%^**a**^**53**5399%3084%15%**62**6299%8185%14%**18151**5199%8285%14%**66**6698%5683%15%^**a**^**68**6898%3981%17%**18258**5898%3387%11%**61**61100%mEV06c12b83%17%**18458**5899%3385%14%**18558**5899%3385%14%**70**7099%3981%18%**89**8999%8178%21%**18816**16100%3578%22%**19156**5699%6683%16%**19251**5198%8284%14%**19362**6299%8185%14%**19552**5299%5881%18%**59**5999%1876%23%**19659**5999%1877%22%**19752**52100%5881%19%**59**5999%1876%23%**70**7099%3981%18%^**a**^**90**9097%10685%12%**198**^**a**^**32**3299%4284%15%**53**5399%3086%13%**56**5699%6684%15%**61**61100%mEV06c12b83%17%**66**6698%5683%15%**84**8499%8784%15%**20053**5398%3085%13%**54**5499%4574%25%**81**8199%6284%15%**83**8395%10282%13%**Average % identity of the best hit98%Average difference15%**^a^ HPV types not detected by LA

Table [8](#Tab8){ref-type="table"} summarizes HPV status of each cytology grading. For high-grade and low-grade squamous intraepithelial lesion (HSIL and LSIL), nearly all specimens were positive for high-risk HPV (HSIL: 4/4, 100%; LSIL: 16/18, 88.89%). For atypical squamous/ glandular cells, about half of the specimens were positive for high-risk HPV (by LA: 19/41, 46.34%; by Nanopore: 18/41, 43.90%). For cases without observable abnormalities, 22.12% (25/113) and 21.24% (24/113) were positive for high-risk HPV by LA and Nanopore, respectively. Table 8Results of Pap smear, LA and Nanopore workflow. The calculations were based 176 quality control-valid specimens with Pap smear results availablePap smear interpretationHPV statusNo. of specimensLANanoporeHSIL (*n* = 4)HR/ HR + non-HR44Non-HR only00Negative00LSIL/ LSIL + ASCH (*n* = 18)HR/ HR + non-HR1616Non-HR only11Negative11AGUS/ ASCH/ ASCUS (*n* = 41)HR/ HR + non-HR1918Non-HR only36Negative1917NIL (*n* = 113)HR/ HR + non-HR2524Non-HR only1818Negative7071

Discussion {#Sec9}
==========

Hong Kong has been one of the Asian regions with the lowest incidence and mortality rate of CC \[[@CR16]\]. This might be attributable to the territory-wide cervical screening program implemented by Department of Health since 2004. The program is well-organized, which involves public education, regular cervical smear and follow-up service for eligible women, and a quality assurance mechanism on key components of the program \[[@CR17]\]. Cytology is the mainstay of primary screening, and high-risk HPV testing may be performed for triage to colposcopy.

Cytology and HPV testing have their own value for CC screening. High quality cytology has high specificity for CC, but with lower sensitivity ranging from 50% suggested by cross-sectional studies to 75% estimated longitudinally \[[@CR18]\]. For HPV testing, the sensitivity was reported to be about 10% higher than cytology, yet with lower specificity \[[@CR18]\]. Complementary use of both tests could enhance the sensitivity approaching 100% with high specificity (92.5%) \[[@CR19]\]. In fact, this combined approach has been adopted by several European countries and may become the future trend of primary CC screening in developed countries.

Compared with HPV assays in the market, HPV genotyping by NGS offers a broader detection spectrum which, despite minimal benefit of non-high risk HPV information for CC screening, may provide important etiologic clues for other HPV-associated infections and a more complete picture of HPV epidemiology. For the latter, Nanopore identified more HPV types per sample (Fig. [1](#Fig1){ref-type="fig"}) and 5 extra HPV types (HPV 43, 44, 74, 87 and 90, *n* = 34) not detectable by LA (Fig. [2](#Fig2){ref-type="fig"}), with an unexpected high incidence of HPV 90 (*n* = 12) which was reported in North America and Belgium but not in Hong Kong \[[@CR20], [@CR21]\]. Another advantage offered by NGS is its potential utility for simultaneous characterization of cervicovaginal microbiome, with its possible role in dysplasia and carcinogenesis revealed by accumulating research evidence \[[@CR22]--[@CR25]\]. These merits may facilitate a multifaceted approach for evaluation of woman health in near feature. Fig. 1Number of HPV types detected per sample by Nanopore workflow and LAFig. 2Diversity of HPV types detected by Nanopore workflow and LA

In general, Nanopore had substantial agreement with cobas HPV Test and LA. Compared with cobas HPV Test, Nanopore appeared to be more sensitive for HPV 52 (*n* = 7) and 59 (*n* = 4), with 81.82% (9/11) of these discrepant results matched with LA. Compared with LA, concordance for high-risk HPV was higher than non-high risk types. Among the 37 discrepant results, 22 were false negatives by Nanopore and 15 were not detected by LA.

For the false negatives by Nanopore, more than half (12/22, 54.55%) were mixed infections, and similar finding was reported by other research groups using HPV consensus primers for NGS-based genotyping \[[@CR10], [@CR11]\]. Other possible causes of false negatives included (1) low viral load, as evident by Specimen 182, from which HPV 16 was missed by both Nanopore and cobas HPV Test; (2) substantial difference in DNA input (50 μL for LA versus 5 μL for PGMY/ MGP PCR), as well as (3) lower sensitivity due to reduced magnesium chloride concentration of PGMY PCR (from 4 mM to 1.5 mM), which was fine-tuned for minimal non-specific amplification.

For the 15 HPV types missed by LA, the average identity of Nanopore consensus sequences was 98.27% with an average difference of 16% from second BLAST hits (Table [7](#Tab7){ref-type="table"}). As distinct HPV types generally have more than 10% difference in L1 sequence \[[@CR26], [@CR27]\], it appeared that the discrepant positive calls were less likely caused by high sequencing error rate of Nanopore. More specifically, 5 of these positive calls were identified solely by MGP PCR (5/15, 33.33%), 5 detected by PGMY PCR only (5/15, 33.33%), and 5 by both PCRs (5/15, 33.33%). These revealed differential sensitivities of PGMY and MGP PCR primers, which might complement with each other and enhance overall performance of the Nanopore assay. On the other hand, Nanopore sequencing might improve the resolution of genotyping, which might not be attained by line blot method due to cross-hybridization of certain probes. For instance, Nanopore identified HPV 52 in Specimen 5, 40 and 74, which could not be confirmed by LA due to cross-hybridization with HPV 33 and 58, respectively. Another example was Specimen 125, which was HPV 84-positive by LA and HPV 87-positive by Nanopore. From literature, Artaza-Irigaray and colleagues reported cross-hybridization between these 2 HPV types by LA, with 11.5% of HPV 84-positive cervical specimens by LA were actually HPV 87-positive by NGS \[[@CR28]\].

The Nanopore method and LA revealed very similar high-risk HPV positivity in each cytology grading. The goal of combined cytology-HPV testing approach is to enhance cost effectiveness of CC screening. While minimizing unnecessary referral for colposcopy, HPV genotyping may identify high-risk individuals before observable cytological abnormalities, for instance, the 4 HPV 16-positive patients without abnormal cytology findings in this study. This may facilitate an early detection approach for cancer prevention.

Our study had several limitations. First, the sample size of certain HPV types, for example, HPV 18 (*n* = 1), was less satisfactory for evaluating type-specific performance. Second, as residual DNA was used after routine testing, DNA input for PGMY and MGP PCRs was constrained which might lower the sensitivity. In addition, as flow cells with suboptimal number of active pores were used, sequencing time and depth might be further improved if new flow cells were used.

Conclusions {#Sec10}
===========

We developed a Nanopore workflow for HPV genotyping, with performance comparable to or better than 2 reference methods in the market. Our method was economical, with a reagent cost of about USD 50.77 per patient specimen for 24-plex runs, which was competitive when compared to an average price of USD 106.14 (from 4 randomly-selected laboratories) for HPV genotyping referral service in our region (Table [9](#Tab9){ref-type="table"}). The protocol was also straightforward with reasonable turnaround time of about 12 h from samples to answers. The small size and portability of MinION sequencers may well suit remote or resource-limited laboratories with constraints in space. Future prospective study with larger sample size is warranted to further evaluate test performance and streamline the protocol. As LA was discontinued in Hong Kong, the Nanopore workflow described here may provide an economical option for broad-range HPV genotyping. Table 9Comparison of estimated reagent cost of Nanopore workflow (24-plex) and randomly-selected prices of HPV genotyping referral service in Hong Kong***This study***ProcedureNumber of specimensCostDNA extraction and PCRs201 patients +20 controls = 221USD 20.02 × 221 reactions = USD 4424.42Nanopore sequencing115 patients / 24 = at least 5 runsN = 120 for 1 positive control per runUSD 1155.94 × 5 runs = USD 5779.70**Cost per patient specimen**(4424.42 + 5779.70) / 201 = **USD 50.77*Referral service (transportation cost not included)***Lab AUSD 77.19Lab BUSD 124.79Lab CUSD 101.63Lab DUSD 120.93**AverageUSD 106.14**
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:   Cervical cancer

HPV

:   Human papillomavirus
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:   High-grade squamous intraepithelial lesion
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LSIL

:   Low-grade squamous intraepithelial lesion

NGS

:   Next-generation sequencing
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